key: cord-0955839-i41btfm5 authors: Sefers, Susan E.; Li, Haijing; Tang, Yi-Wei title: Simultaneous Detection and Differentiation of Respiratory Syncytial Virus and Other Respiratory Viral Pathogens date: 2010-08-16 journal: Diagnostic Virology Protocols DOI: 10.1007/978-1-60761-817-1_17 sha: 2ff6546532dce5db563cbdbf3ea6f3a95d81a2b8 doc_id: 955839 cord_uid: i41btfm5 Rapid and accurate detection of respiratory syncytial virus (RSV) provides pathogen-specific diagnosis, allows implementation of appropriate infection control measures, and improves patient management. One diagnostic challenge is that respiratory infections, which can be caused by several viral pathogens including RSV, usually present with similar signs and symptoms that are nearly indistinguishable by clinical diagnosis. We have described in the chapter a rapid, high-throughput laboratory technique that can detect a panel of common viral pathogens in one single reaction. With the combination of target-enriched multiplexing PCR amplification and Luminex suspension array identification, 12 common respiratory viruses, including RSV A and B, influenza virus A and B, parainfluenza virus 1, 2, 3, and 4, human metapneumovirus, rhinoviruses, enteroviruses, and SARS coronavirus, are detected and differentiated simultaneously within five hours. clinical manifestations and outcomes (6, 7) . RSV causes hazardous nosocomial infection and produces outbreaks each year with widespread infections in both children and adults, including medical personnel, who may have a mild enough illness that does not cause absences from work. Furthermore, the spread of the virus is facilitated by the number of young infants admitted during an outbreak who tend to shed high titers of virus for prolonged periods (8) . Other viruses that can mimic RSV infection include adenoviruses, influenza virus (INF) A and B, parainfluenza viruses (PIV), human metapneumovirus (hMPV), and rhinoviruses. Patients with acute respiratory infections can present with similar signs and symptoms regardless of the viral pathogen, and clinical differential diagnosis of infections caused by these viruses can be difficult. Early and accurate virus-specific laboratory diagnosis significantly enhances patient management. There are currently a variety of laboratory tests available to detect and differentiate respiratory viruses, which have been developed over the last two decades. The use of rapid tests in the diagnosis of RSV infection allows implementation of appropriate infection control measures, thus reducing nosocomial spread (9) and may be useful for consideration of timely treatment with aerosolized ribavirin in severe cases. Direct fluorescent antibody (DFA) tests have good sensitivity for RSV, but are not as good for other respiratory viruses (10, 11) . Rapid EIA antigen tests are available for RSV and Influenza A and B; they are easy to perform, and more rapid than DFA, but have slightly lower sensitivity and specificity (12, 13) . Among the respiratory viruses mentioned previously, the vast majority will be grown in traditional viral culture cell lines used in clinical virology laboratories with the exception of hMPV, which is not yet widely used in routine diagnostic laboratories (14) . Furthermore, cell culture has a slow turnaround time with most viruses showing no detectable cytopathic effects until 3 to 14 days later. However, a shell vial technique incorporated with mixed fresh cells (R-Mix, Diagnostic Hybrids, Inc., Athens, OH) can be performed which speeds up the turnaround time to 2 days and has a sensitivity similar to conventional cell culture (15) . The diagnosis of RSV infections using serology has no practical applications in clinical use. As is the case with other respiratory viral pathogens, molecular assays based on in vitro nucleic acid amplification have been implemented gradually in clinical laboratories for RSV detection. These molecular assays, led by PCR, in general, have demonstrated to be superior to routine diagnostic methods in terms of their high sensitivity and specificity (16) (17) (18) , which are especially useful in adult patients when viral shedding is short and low (19, 20) . While cell culture remains the gold standard for RSV diagnosis, the molecular assays have been considered the "platinum" standard to be used as the reference to validate new diagnostic kits for RSV detection (2, 12) . However, these organism-specific monoplex assays are resource-intensive; when a respiratory viral infection is considered, the list of possible etiologies is necessarily long. Multiplex RT-PCR-based techniques have widely been reported for simultaneous detection of a panel of respiratory viral pathogens in a single reaction (21) (22) (23) (24) (25) . Several products, including the Hexaplex assay (Prodesse, Waukesha, WI), the PLx-RVP assay (EraGen Biosciences, Madison, WI), the ID-Tag RVP (TM Biosciences, Toronto, Canada), and the ResPlex II (Qiagen, Valencia, CA), are commercially available (22, (26) (27) (28) (29) (30) . This chapter describes a complete molecular diagnostic procedure covering common RNA viral pathogens causing respiratory tract infections. The following procedure consists of three components (Fig. 1 ). The first, specimen processing and nucleic acid extraction, is done by using an easyMAG automated total nucleic acid extraction instrument (bioMerieux, Durham, NC), based on a magnetic silica particle-based technique (31) . The kits are available from bioMerieux and work on a variety of clinical specimens, including nasopharyngeal swabs and aspirates and yields high quantity and quality total nucleic acids (32) . The second, nucleic acid amplification, uses a target-enriched multiplexing (TEM)-PCR (33) , which contains two nested primer sets for each organism and a set of Super Primers, to simultaneously amplify INF-A, INF-B, PIV-1, PIV-2, PIV-3, PIV-4, RSV-A, RSV-B, hMPV, rhinoviruses (RhV), enteroviruses (EnV), and severe acute respiratory syndrome (SARS) coronavirus (CoV) gene in a single reaction tube (27, 29) . The target gene from each of the viruses is listed in Table 1 . The third, amplicon detection and identification, is reached by using a microspherebased liquid array (Luminex, Austin, TX). A median fluorescence intensity (MFI) is reported for each target. A positivity cut-off is used to determine if the sample is positive for a particular target (34, 35) . The last amplification and detection components are included in the ResPlex II kit, which is available from Qiagen. Durham, NC). 2. GeneAmp 9700 PCR System (Applied Biosystems) using 9600 emulation mode. 2. Begin the extraction request by entering the sample type. With each sample entry, confirm the type of sample. These should be set to "other" and "primary." 3. Define the sample volume and elution volume. For extraction on nasal collections, program a 0.2 mL sample volume with a 55 mL elution volume. 4. Ensure the protocol is Generic. 6. After all samples are entered, press the Organize Runs icon (opposing arrows). 7. Create a new run by pressing the New Run icon (sun). 8. Enter a run name, and then press OK. 9. Create the run layout using the arrow icons to arrange the sample list in the correct order for your run. 10. Press the Load Run (instrument with bottles) icon. 11. Place the sample tray and pipette tips in the correct positions. 12. Using the barcode scanner, scan in the position and the sample tray for each position. 13. Press the Printer Icon to print the run. Press OK on the print window when it appears. 14. Pull the sample tubes from the instrument and place them in the metal sample rack. 15. Pipette 200 mL of sample into each sample tube. Use the printout as a guide. 16 . When finished, place the sample tray back into the instrument. The position and sample tray will have to be scanned into the instrument. Close the lid of the sample module. 17. Press the Add Lysis icon. The lysis buffer will be added by the instrument and incubated for approximately 10 min. 18. While the sample is lysing on the instrument, prepare the magnetic silica. 19. Prepare the magnetic silica, using the multichannel pipette, choose program 1 (Press the Select button until P1 is displayed and then press Enter. 29. The run will continue until all samples are completed. "Finished" will display on the bar at the bottom of the screen. While the run is in progress, label a 1.5-mL tube for each sample and control for long-term storage. 30. Complete the run by pressing the View Results Icon (Magnifying Glass). 32. The report will print. A window will pop up reading "The run results are being printed. Mark this run ASSESSED?" Press Yes. 33. Quickly check the report for any errors. If an error was signaled, repeat the extraction and refer to troubleshooting. 1. Before using AmpCheck reagent for the first time, make a 1/50 dilution by adding 245 mL RNase-free water into the tube containing the 5 mL AmpCheck and mix. 2. Make sure the thermal cycler is preheated to 50°C before placing samples into the unit. 3. Thaw the template RNA, dNTP Mix, 5× QIAGEN OneStep RT-PCR Buffer, and RNase-free water, and place them on ice. NOTE: It is important to mix the solutions completely before use to avoid localized differences in salt concentration. 5. Prepare the detection mix according to Table 4 . Table 5 provides an example of data, from a ResPlex II Table 5 Example run. The positivity cutoff is dependent on the instrument and software used for analysis. The cutoff value for each target is determined as the sum of the mean plus four times the standard deviations of the negative controls. 3. Set up all RT-PCR reactions on ice. RNA is the target, which is fragile. Keeping the reaction mixes cold will reduce RNA degradation. 4. Use disposable, RNase-free tips containing hydrophobic filters to minimize cross-contamination. 5. Use of the GeneAmp 9700 PCR System (Applied Biosystems) running in the 9600 emulation mode for the amplification step is recommended. Performance of this protocol using other equipment has not been verified yet. 6. From the beginning of the hybridization procedure in the detection step, the detection reaction must be kept at 52°C until analysis on the LiquiChip 200 Workstation. 7. Protect the ResPlex II Bead Mix and reaction mix from light. Foil should be used to cover the tubes and 96-well plate. 8 . In a clinical validation study on 360 archived frozen nasopharyngeal swabs and aspirates, the sensitivity and specificity for RSV detection were 73.3 and 100%, when compared to a standard combined from cell culture and monoplex real-time TaqMan PCR. Sensitivities and specificities were 72.2-90% and 99.7-100%, respectively, for other respiratory viruses. When a full panel (96 tests) was run, the hands-on time and the test turnaround time were estimated as 55 min and 6 h, respectively (27) . 9. There is no validation data on PIV-2, PIV-4, enterovirus, and rhinovirus. There is some cross-reactivity between PIV-1 and PIV-3 in the ResPlex assay; of 27 samples testing positive for parainfluenza, eight samples (29.6%) had IMF values higher than the cutoff values for PIV-1 and PIV-3 (27) . 10 . The assay was useful to detect and recognize viral coinfections, which are usually related to more severe clinical manifestations (30). 11. Respiratory DNA viruses, such as bocavirus (36) , adenovirus, and a recently reported respiratory polyomavirus (37), were not covered in the ResPlex II kits evaluated in the study. A new version of the ResPlex II kit, which covers bocavirus and adenovirus in addition to those described in the chapter, has been available from Qiagen since July 2008. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment Respiratory syncytial virus and human metapneumovirus Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada Respiratory syncytial viral infection in infants with congenital heart disease Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up Correlation between respiratory syncytial virus genotype and severity of illness Severity of respiratory syncytial virus infection is related to virus strain Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study SimulFluor respiratory screen for rapid detection of multiple respiratory viruses in clinical specimens by immunofluorescence staining Prospective evaluation of rapid antigen tests for diagnosis of respiratory syncytial virus and human metapneumovirus infections Comparison of two new rapid antigen detection assays for respiratory syncytial virus with another assay and shell vial culture Analysis of replication kinetics of the human metapneumovirus in different cell lines by real-time PCR R-Mix cells are faster, at least as sensitive and marginally more costly than conventional cell lines for the detection of respiratory viruses Detection of respiratory syncytial virus by reverse transcription-PCR and hybridization with a DNA enzyme immunoassay Improved detection of respiratory syncytial virus in nasal aspirates by seminested RT-PCR A colorimetric microtiter plate PCR system detects respiratory syncytial virus in nasal aspirates and discriminates subtypes A and B Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients Multiplex realtime PCR assay for detection of influenza and human respiratory syncytial viruses Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex) Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study Comparison of a multiplex reverse transcription-PCR-enzyme hybridization assay with conventional viral culture and immunofluorescence techniques for the detection of seven viral respiratory pathogens Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses Simultaneous detection and highthroughput identification of a panel of RNA viruses causing respiratory tract infections Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay Direct screening of clinical specimens for multiple respiratory pathogens using the Genaco Respiratory Panels 1 and 2 Evidence from multiplex molecular assays for complex multipathogen interactions in acute respiratory infections Rapid and simple method for purification of nucleic acids Comparative evaluation of three commercial systems for nucleic acid extraction from urine specimens Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP system Advanced multiplexed analysis with the FlowMetrix system Cloning of a human parvovirus by molecular screening of respiratory tract samples Identification of a third human polyomavirus Estes for their excellent technical support. This project was partially supported by a research and development grant from Qiagen. The protocol contains partial information in product inserts of the easyMAG and the ResPlex II kits and the Standard Operating Manual of the Molecular Infectious Disease Laboratory, Vanderbilt University Hospital.